16 September 2026 editorial review · Trial
iPSC-derived islet cells for diabetes (Peking University First Hospital): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Removed inference that registry proves nobody dosed; distinguished estimated enrollment, mixeddiabetes eligibility and no established drug-free protocol.
Registry: NCT07464119. Endpoint reviewed: Adverse events (From enrollment to month 6). Eligibility reviewed: Age 18 Years to unspecified; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Additional source access: Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient.; Illuminating the future of diabetes treatment: Autologous CiPSC-derived islets take center stage..